LTX-608 is under clinical development by Talphera and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how LTX-608’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LTX-608 overview
Nafamostat mesylate (LTX-608) is under development for the treatment of COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS) and acute pancreatitis. The therapeutic candidate is a new chemical entity. It is administered through intravenous route. It acts by targeting transmembrane protease serine 2 (TMPRSS2).
Talphera overview
Talphera, formerly AcelRx Pharmaceuticals, is a specialty pharmaceutical company. It focuses on developing and commercializing therapies for medically supervised environments, with nafamostat as the foundation of its pipeline. The lead product candidate, Niyad, is a lyophilized formulation of nafamostat designed as a regional anticoagulant for dialysis circuits. Talphera is advancing LTX-608 for broader applications in inflammatory diseases and viral infections, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. The company is also developing pre-filled syringes, including Fedsyra for the treatment of hypotension during general anesthesia, and PFS-02 for managing hypotension and clotting disorders. Talphera is headquartered in San Mateo, California, the US.
For a complete picture of LTX-608’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
